Clinical trials: Arthritis, Rheumatoid
Rheumatoid Arthritis
Observational Trial With Enbrel
The diagnosis, evaluation and treatment of rheumatoid arthritis (RA) continue to undergo rapid change. Randomized controlled trials such as the TEMPO study have demonstrated the efficacy and safety of the combination of…
- Trial name
- NCT00488475
- Testing
- etanercept
- Where
- Germany
- Volunteers
- 4,945 people
- Sponsor
- Pfizer
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset…
- Conditions
- Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
- Trial name
- NCT03311854
- Testing
- Emapalumab
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- Swedish Orphan Biovitrum
Rheumatoid Arthritis
An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA
An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of RemsimaTM in Patients with Rheumatoid Arthritis.
- Trial name
- NCT02557295
- Volunteers
- 248 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.
This single arm study will assess the effectiveness of tocilizumab in combination with traditional DMARDs with regard to the clinical improvement in disease activity (achievement of LDAS) after 24 weeks' treatment in patients…
- Trial name
- NCT00754559
- Testing
- Tocilizumab
- Where
- 81 sites in Germany
- Volunteers
- 286 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX
To address the objectives, a retrospective cohort design will be employed to evaluate patient characteristics, treatment patterns, medication effectiveness, and health care cost and utilization in RA patients newly initiating…
- Trial name
- NCT03975790
- Where
- United States
- Volunteers
- 479 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)
This Phase IIIb, randomized, multi-national, multi-center, blinded study of Infliximab (IFX) in subjects aged 18 and older with active RA is being conducted to assess whether increasing either the infusion dose or infusion…
- Trial name
- Re³ (NCT00394589)
- Testing
- Infliximab Increased Frequency, Infliximab Increased Dose, Infliximab Control
- Volunteers
- 43 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study (Dose)
The primary purpose of this observational study is to describe and define the current daily practice of management of anti-TNF-agents in Rheumatoid Arthritis (RA) patients.
- Trial name
- DOSE (NCT00794118)
- Testing
- As per clinical practice
- Where
- Italy
- Volunteers
- 299 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis
The overall objective of the study is to assess the effectiveness of switching from immediate-release prednisone (conventional) therapy to delayed-release prednisone (RAYOS) in patients with moderately to severely active…
- Trial name
- SUNRAY (NCT02287610)
- Testing
- RAYOS (delayed-release prednisone)
- Volunteers
- 75 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study
This is an observational study of composite indices, including the CLARA (CLinical ARthritis Activity) index, in rheumatoid arthritis (RA) patients in routine clinical practice in Italy in order to evaluate clinical remission and…
- Trial name
- New Indices (NCT00793403)
- Testing
- As per routinary clinical care
- Where
- Italy
- Volunteers
- 293 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis
The purpose of the study is to compare the safety and efficacy, with regards to the signs and symptoms, of MR prednisone (Lodotra®) versus placebo in combination with standard Disease Modifying Anti-Rheumatic Drug (DMARD)…
- Trial name
- CAPRA-2 (NCT00650078)
- Testing
- MR prednisone
- Where
- 52 sites in United States, Canada and 4 more
- Volunteers
- 350 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
The purpose of this study is to assess the ability of people with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) to use an experimental autoinjector to self inject etanercept (Enbrel®).
- Trial name
- NCT01901185
- Testing
- Etanercept / Autoinjector A
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Hypovitaminosis D
Treatment of Hypovitaminosis D in Rheumatoid Arthritis
This study recruits individuals with rheumatoid arthritis (RA) and low vitamin D concentrations. Subjects are dosed with vitamin D or placebo for one year.
- Trial name
- NCT00423358
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Arthritis, Rheumatoid
A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients
The purpose of the study is to compare the long-term safety, effectiveness and immunogenicity of FKB327 in comparison to Humira® in rheumatoid arthritis patients who have completed study FKB327-002 and have inadequate disease…
- Trial name
- ARABESC-OLE (NCT02405780)
- Testing
- FKB327, Humira®
- Where
- 92 sites in United States, Canada and 9 more
- Volunteers
- 645 people
- Sponsor
- Fujifilm Kyowa Kirin Biologics Co., Ltd.
Arthritis, Rheumatoid
A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting
This study is to characterize the use of tofacitinib after use of rituximab in patients with Rheumatoid Arthritis in a real-world setting.
- Trial name
- NCT05487703
- Where
- Morocco
- Volunteers
- 318 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.
This study will provide efficacy and safety data of the secukinumab pre-filled syringe (PFS) for subcutaneous self-administration in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate…
- Trial name
- REASSURE2 (NCT01770379)
- Testing
- Secukinumab (AIN457)
- Where
- 77 sites in United States, Argentina and 14 more
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044
This study will continue to evaluate the safety \& efficacy of Certolizumab Pegol (CZP) for 6 months in Chinese subjects with active Rheumatoid Arthritis who participated in RA0044.
- Trial name
- RAPID-C OLE (NCT02319642)
- Testing
- Certolizumab Pegol
- Where
- 30 sites in China
- Volunteers
- 347 people
- Sponsor
- UCB Pharma SA
Rheumatoid Arthritis
Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis
The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving pain associated with rheumatoid arthritis (RA) compared with placebo and naproxen (similar to Aleve®).
- Trial name
- NCT00626275
- Testing
- ADL5859, Naproxen
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
This study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-TNF alpha inhibitor.
- Trial name
- NCT02079532
- Testing
- rituximab [MabThera]
- Where
- 69 sites in Germany
- Volunteers
- 302 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate.
- Trial name
- STAGE (NCT00406419)
- Testing
- Methotrexate, ocrelizumab
- Where
- United States
- Volunteers
- 1,015 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice
Defining Which Remission Criterion at Month 6 Predicts Remission at Month 12 in a Real Life Clinical Practice, in a Cohort of Rheumatoid Arthritis Patients Treated with Etanercept
- Trial name
- REACH RA (NCT02202837)
- Testing
- etanercept
- Where
- 35 sites in Belgium
- Volunteers
- 157 people
- Sponsor
- Pfizer